Gilead Sciences FY2026 EPS Increased by Erste Group Bank

Key Points

• Erste Group Bank raised its FY2026 EPS estimate for Gilead Sciences to $(0.44) from $(0.45), compared with the consensus estimate of $(0.48).
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $158.78, although several firms recently lowered their targets.
• Gilead reported quarterly revenue of $7.80 billion, up 10.6% year over year, and beat the EPS consensus estimate; the company also declared a quarterly dividend of $0.82 per share, yielding about 2.2% annually.

Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Equities researchers at Erste Group Bank increased their FY2026 earnings per share estimates for Gilead Sciences in a research report issued on Friday, September 18th. Erste Group Bank analyst H. Engel now anticipates that the biopharmaceutical company will post earnings of ($0.44) per share for the year, up from their prior estimate of ($0.45). The consensus estimate for Gilead Sciences' current full-year earnings is ($0.48) per share.

Several other equities research analysts also recently weighed in on GILD. Morgan Stanley decreased their price target on shares of Gilead Sciences from $166.00 to $165.00 and set an "overweight" rating for the company in a research note on Monday, July 27th. Leerink Partners cut shares of Gilead Sciences from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. Zacks Research upgraded Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Monday, August 31st. Barclays decreased their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 29th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $155.00 price target on shares of Gilead Sciences in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of "Moderate Buy" and an average target price of $158.78.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $150.56 on Tuesday. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $186.69 billion, a P/E ratio of -56.39 and a beta of 0.33. The company has a fifty day moving average of $140.37 and a 200-day moving average of $136.24. Gilead Sciences has a twelve month low of $108.46 and a twelve month high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.25) by $0.50. The firm had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The company's revenue was up 10.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.01 earnings per share.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. bought a new position in shares of Gilead Sciences in the second quarter worth $15,393,785,000. State Street Corp lifted its holdings in Gilead Sciences by 1.9% during the 4th quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company's stock worth $7,393,921,000 after purchasing an additional 1,151,213 shares in the last quarter. Norges Bank bought a new position in Gilead Sciences in the 4th quarter worth about $2,617,152,000. Invesco Ltd. grew its holdings in Gilead Sciences by 2.9% during the 4th quarter. Invesco Ltd. now owns 15,584,341 shares of the biopharmaceutical company's stock valued at $1,912,822,000 after buying an additional 444,660 shares in the last quarter. Finally, Amundi increased its position in shares of Gilead Sciences by 10.7% during the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company's stock valued at $1,468,836,000 after buying an additional 1,018,976 shares during the period. 83.67% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the firm's stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $145.29, for a total value of $435,870.00. Following the completion of the sale, the chief financial officer directly owned 164,096 shares of the company's stock, valued at $23,841,507.84. This trade represents a 1.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the business's stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $145.02, for a total value of $725,100.00. Following the completion of the sale, the director owned 10,066 shares in the company, valued at approximately $1,459,771.32. The trade was a 33.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 105,000 shares of company stock worth $14,616,390 in the last three months. Insiders own 0.30% of the company's stock.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. Gilead Sciences's dividend payout ratio (DPR) is presently -122.85%.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company's research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.

Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.